相关实验视频

Updated: May 29, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

功能化纳米颗粒对胆固醇有效抗击Helicobacter pylori,胃病菌:一项概念验证研究

Ana Sofia Pinho^1,2,3, Renato Pereira^1,2,4, Mariana Pereira^1,2

¹i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, R. Alfredo Allen 208, Porto, 4200-135, Portugal.

Advanced healthcare materials

|February 6, 2025

概括

植入胆固醇的纳米颗粒提供了一种新的治疗策略,可以对抗胃癌的主要原因 - - 杆菌. 这些纳米粒子通过破裂它们的膜来有效地杀死细菌,显示出新的治疗方法的希望.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
微生物学微生物学

背景情况:

慢性Helicobacter pylori感染是胃癌的主要危险因素.
增加H. pylori的抗生素耐药性需要新的治疗方法.
胆固醇移植纳米粒子 (Chol-NP) 被提出作为一种"特洛伊木马"战略.

研究的目的:

为了证明H. pylori对胆固醇的特定结合.
评估胆固醇功能化纳米颗粒对H.pylori的疗效.
评估Chol-NP的安全性和生物相容性.

主要方法:

在黄金基板上制造胆固醇功能化自组装单层 (Chol-SAM).
胆固醇移植纳米粒子 (Chol-NP) 的制备和表征.
最低杀菌度 (MBC) 确定和传输电子显微镜 (TEM) 用于作用机制研究.
使用AGS细胞系和溶血活性测试进行细胞毒性测试.
对肠道微生物群 (大肠杆菌,L. acidophilus) 的影响评估.

主要成果:

杆菌证明了对2DChol-SAMs的度依赖的附着性.
通过25%的胆固醇-聚乙烯糖醇 (PEG) - thiol.thiol,可以实现最佳的Chol-SAM.
在最小杀菌度为125μg mL−1.1.1的Chol-NP消除了H. pylori.
TEM发现,Chol-NP通过内部化和膜破裂来杀死H. pylori.
霍尔-NP表现出细胞兼容性,非溶血性,对肠道细菌是安全的.

结论:

胆固醇功能化使得特定的细菌向和纳米粒子介导的H.pylori.根除成为可能.
霍尔-NP代表了一种有前途的,生物相容的治疗剂,可以对抗H. pylori感染.
对胆固醇功能化生物材料的进一步开发有助于先进的H. pylori治疗.

关键词:

在Helicobacter Pylori的研究中,没有抗生素的策略.生物工程是生物工程.金纳米颗粒的金子纳米颗粒脂质脂质脂质是一种自己组装的单层单层.

更多相关视频

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.